Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
- Status
- TERMINATED
- Phase
- PHASE4
Clinical Trials Related to Boehringer Ingelheim
Related studies linked through entity extraction aliases.
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
Investigation of Single Rising Doses of BI 685509
- Status
- COMPLETED
- Phase
- PHASE1
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Withdrawal of Inhaled Corticosteroids in Primary Care Patients With COPD
- Status
- UNKNOWN
- Phase
- NA
Weekly BI 836880 in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
SATisfaction and Adherence to COPD Treatment
- Status
- COMPLETED
- Phase
- N/A
Patient Convenience Study (RE-SONANCE)
- Status
- COMPLETED
- Phase
- N/A
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke
- Status
- COMPLETED
- Phase
- NA
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
Airway Effects of Tiotropium in Patients With COPD
- Status
- COMPLETED
- Phase
- PHASE3
Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
- Status
- COMPLETED
- Phase
- PHASE4
Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice
- Status
- COMPLETED
- Phase
- N/A
Dose Finding Study of BI 836880 in Patients With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
- Status
- COMPLETED
- Phase
- PHASE3
LUME BioNIS: a Biomarker Study in Patients With NSCLC
- Status
- COMPLETED
- Phase
- N/A
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Influence of Bosentan on the Pharmacokinetics of Nintedanib
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
- Status
- COMPLETED
- Phase
- PHASE1